Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Universal CD19/BCMA CAR T-cells in Relapsed/Refractory Neurological Autoimmune Diseases
NCT06939166Phase 1Recruiting
- Sponsor
- Tianjin Huanhu Hospital
- Start
- Jun 2025
- Primary completion
- Apr 2026
- Modality
- CAR-T Cells
- Countries
- 1
01
Overview
Phase 1, open-label, single-arm trial of anti-CD19/BCMA CAR T-cells in Neuromyelitis Optica Spectrum Disorder (NMOSD), myasthenia gravis (MG), multiple sclerosis (MS) and 2 more, sponsored by Tianjin Huanhu Hospital. Primary endpoints: Dose-Limiting Toxicity at 28 days and Adverse Events at 90 days. Started Jun 2025; status: recruiting.
02
Drugs
anti-CD19/BCMA CAR T-cells
03
Conditions
Neuromyelitis Optica Spectrum Disorder (NMOSD)myasthenia gravis (MG)multiple sclerosis (MS)chronic inflammatory demyelinating polyradiculoneuropathy (CIDP)Autoimmune Encephalitis (AE)
Beyond the preview
Go deeper on NCT06939166.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT06939166.